Review Article
The Protective Effects and Potential Mechanisms of Ligusticum chuanxiong: Focus on Anti-Inflammatory, Antioxidant, and Antiapoptotic Activities
Table 2
Diseases ameliorated by LC.
| Disease | Drug | Dosage (mg/kg) | Model | Ref |
| Atherosclerosis | Total lactone | 30, 60 | ApoE-/- mice | [56] | Cerebral trauma | Ligustrazine | 20 | Controlled cortical impact mice | [49] | Migraine | Senkyunolide I | 16, 32 | Nitroglycerin-treated rats | [58] | Diabetic nephropathy | Ethanol extraction | 25, 50, 100 | Streptozotocin-treated mice | [24] | Intervertebral disc degeneration | Ligustilide | 10 | Mice treated by surgery | [42] | Oxidative damage on renal | Ligustrazine | 80 | Gentamicin-treated mice | [59] | Ischemic cerebral stroke | Senkyunolide I | 36, 72 | Ischemia-reperfusion injured rats | [53] | Cognitive impairment | Ligustilide | ā | D-galactose-treated mice | [60] |
|
|